55
Participants
Start Date
July 8, 2019
Primary Completion Date
August 1, 2021
Study Completion Date
August 1, 2021
PARP inhibitor and Anti-PD-L1
olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
Amsterdam UMC, AMC, Amsterdam
NKI-AVL, Amsterdam
Universitair Medisch Centrum Groningen, Groningen
Academisch Ziekenhuis Maastricht, Maastricht
RadboudMC, Nijmegen
Erasmus MC, Rotterdam
Universitair Medisch Centrum Utrecht, Utrecht
Leiden University Medical Center, Leiden
Collaborators (2)
Amsterdam University Medical Center
OTHER
Erasmus Medical Center
OTHER
Maastricht University Medical Center
OTHER
The Netherlands Cancer Institute
OTHER
Radboud University Medical Center
OTHER
University Medical Center Groningen
OTHER
UMC Utrecht
OTHER
AstraZeneca
INDUSTRY
Leiden University Medical Center
OTHER